Put me down for being skeptical that such an ABT combo will compare favorably to a PI+NS5A+nuke combo.
Although I still think GILD will have the best combo, I'm not as skeptical as a few weeks ago on ABT.
I recall IDIX speaking on several occasions of non-nukes being the weakest link in their pre-clinical HCV DAA combo studies. And obviously, nukes have performed much better by themselves in the clinic than non-nukes.
Absolutely true that nukes are superior probably in every aspect but even nukes aren't perfect and ABT's all-oral HCV nukeless combo could be competitive at least in GT1 naïve patients. Again, GILD and BMY seem to have better combos but I would not write ABT off yet, something goes wrong there and ABT wins.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.